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Abstract
Background: Bcl-2 family proteins are key regulators of mitochondrial integrity and comprise both pro-
and anti-apoptotic proteins. Bax a pro-apoptotic member localizes as monomers in the cytosol of healthy
cells and accumulates as oligomers in mitochondria of apoptotic cells. The Bcl-2 homology-3 (BH3) domain
regulates interactions within the family, but regions other than BH3 are also critical for Bax function. Thus,
the N-terminus has been variously implicated in targeting to mitochondria, interactions with BH3-only
proteins as well as conformational changes linked to Bax activation. The transmembrane (TM) domains
(α5-α6 helices in the core and α9 helix in the C-terminus) in Bax are implicated in localization to
mitochondria and triggering cytotoxicity. Here we have investigated N-terminus modulation of TM
function in the context of regulation by the anti-apoptotic protein Bcl-xL.
Results: Deletion of 29 amino acids in the Bax N-terminus (Bax 30–192) caused constitutive accumulation
at mitochondria and triggered high levels of cytotoxicity, not inhibited by Bcl-xL. Removal of the TM
domains (Bax 30–105) abrogated mitochondrial localization but resulted in Bcl-xL regulated activation of
endogenous Bax and Bax-Bak dependent apoptosis. Inclusion of the α5-α6 helices/TMI domain (Bax 30–
146) phenocopied Bax 30–192 as it restored mitochondrial localization, Bcl-xL independent cytotoxicity
and was not dependent on endogenous Bax-Bak. Inhibition of function and localization by Bcl-xL was
restored in Bax 1–146, which included the TM1 domain. Regardless of regulation by Bcl-xL, all N-terminal
deleted constructs immunoprecipitated Bcl-xLand converged on caspase-9 dependent apoptosis
consistent with mitochondrial involvement in the apoptotic cascade. Sub-optimal sequence alignments of
Bax and Bcl-xL indicated a sequence similarity between the α5–α6 helices of Bax and Bcl-xL. Alanine
substitutions of three residues (T14A-S15A-S16A) in the N-terminus (Bax-Ala3) attenuated regulation by
the serine-threonine kinase Akt/PKB but not by Bcl-xL indicative of distinct regulatory mechanisms.
Conclusion: Collectively, the analysis of Bax deletion constructs indicates that the N-terminus drives
conformational changes facilitating inhibition of cytotoxicity by Bcl-xL. We speculate that the TM1 helices
may serve as 'structural antagonists' for BH3-Bcl-xL interactions, with this function being regulated by the
N-terminus in the intact protein.
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Bcl-2 family proteins are central to the regulation of mito-
chondrial integrity and cell death pathways that converge
on this organelle [1,2]. This family comprises both pro-
survival (Bcl-2, Bcl-xL, Mcl-1, Bcl-w) and pro-apoptotic
(Bax, Bak, Bim, Bid, Bad) proteins. All members of this
family are characterized by the presence of BH (Bcl-2
homology) domain(s) [3,4]. Bax is a multidomain pro-
apoptotic member of the Bcl-2 family, characterized by
the presence of BH 1–3 domains. The BH3 domain regu-
lates Bax homodimerization as well as heterodimeriza-
tion with Bcl-2/Bcl-xL[5,6], such that the Bax-BH3 domain
docks into the hydrophobic groove formed by BH1, BH2
and BH3 domains of the anti-apoptotic proteins [7-9].
Selectivity in interactions between pro- and anti-apoptotic
members of the Bcl-2 family has been reported [10].
Changes in Bax conformation and localization are charac-
teristic of many cells undergoing apoptosis [11-13]. In
dying cells a conformationally distinct form of (activated)
Bax accumulates at the mitochondrial outer membrane
triggering the release of apoptogenic intermediates
sequestered in the mitochondrial intermembrane space
[14]. Several studies have yielded insights on the molecu-
lar mechanisms regulating Bax activation [15-18] and the
N-terminus is implicated in this function. Controlled
cleavage of the Bax N-terminus by calpain, a Ca2+-depend-
ent cysteine protease generates a dominantly active form
of Bax [19-21]. Short forms of Bax deleted of the first 28
or 32 amino acids are highly cytotoxic, largely associated
with mitochondrial membrane and poorly inhibited by
ectopically expressed Bcl-2 and Bcl-xL [22,23]. Two splice
variants Bax ψ and Bax κ lack 19 amino acids present at
the N-terminal of Bax-α and are potent inducers of cyto-
toxicity when ectopically expressed in cells [24,25].
Specific regions in the N and C terminus are implicated in
the regulated mitochondrial targeting of Bax [26-28].
However, recombinant Bax protein lacking these regions
retains mitochondrial targeting and insertion capabilities
[27,29,30] because of two putative transmembrane (TM)
regions, one encompassing the α5–α6 helices (amino
acids 110–146) and the second the α9 helix (amino acids
172–188) at the C-terminus [31]. These are referred to as
TM1 and TM2 respectively in this study. Recent experi-
ments have shown that both TM1 and TM2 span the lipid
bilayer in the membrane fraction of cells undergoing
apoptosis [32]. Additionally other reports have identified
a role for the α5–α6 helices in mitochondrial membrane
insertion and cytochrome c release [29,33]. In the present
study the TM1 domain and N-terminus have been charac-
terized in the context of regulation of activity by Bcl-xL.
Specifically, the experiments suggest that interactions
between the N-terminus and TM1 region in intact Bax,
modulate susceptibility to inhibition by Bcl-xL.
Results
Apoptosis triggered by a Bax N-terminal deletion mutant 
(Bax 30–192) is poorly inhibited by the anti apoptotic 
proteins, Bcl-2 and Bcl-xL
Apoptosis triggered by a deletion mutant that lacks the
first 29 amino acids (Bax 30–192) was poorly inhibited by
Bcl-xL (Figure 1A) or Bcl-2 (Figure 1B) in the Jurkat T-cell
line. Since Bcl-2 or Bcl-xL function may be modulated by
other pro-apoptotic proteins present in mammalian cells,
we turned to the heterologous system of Drosophila mela-
nogaster, which expresses only one pro- and one anti-
apoptotic protein of the Bcl-2 family [34]. We hypothe-
sized that by expressing these proteins in  Drosophila,
modulation by an endogenous modifier (if indeed it
occurs)  will be independent of the construct being tested
and will be equivalent  in all conditions.
Bax-GFP, Bax 30–192-GFP and Bcl-2 were cloned into the
pUAST vector and expression of the tagged proteins at the
appropriate molecular weights confirmed in the Dro-
sophila S2 cell line (Figure 2A). Transgenic fly lines of Bax,
Bax 30–192 and Bcl-2 were generated by independent P-
element transformation of the UAS-Bax-GFP (BA64III and
BA13I), UAS-Bax30–192-GFP (DBA8II and DBA8IA) and
UAS-Bcl-2 (BC57I and BC24III) constructs. Using the
UAS-GAL4 system both Bax and Bax 30–192 were lethal to
flies when driven in various tissues while Bcl-2 expression
alone was not lethal (Table 1). This allowed us to test for
the rescue of lethality by Bcl-2.
For these experiments, vg-GAL4 and twist-GAL4 lines were
used to drive expression largely in the dorsal margins of
wings and mesoderm respectively. When driven along
with Bax (BA64III, BC57I) using vg-GAL4 (Figure 2Bleft
panel) or twist-GAL4 (Figure 2B, right panel) Bcl-2 rescued
Bax induced lethality whereas Bax 30–192 (DBA8II,
BC57I) induced lethality was only marginally rescued.
Flies expressing Bax or Bax 30–192 (using vg-GAL4)
present deformity in wings to various degrees (Figure 2I).
All the flies that emerged for Bax (BA64III) and Bax 30–
192 (DBA8II) presented a strong wing defect (Figure 2D
and 2E). Bcl-2 co expression with Bax in the double trans-
genic fly line BA64III, BC57I resulted in complete rescue
of the wing defect (Figure 2G) while there was no change
in the severe wing defect in Bax 30–192 and Bcl-2
(DBA8II, BC57I) expressing flies (Figure 2H). Additional
transgenic fly lines of UAS-Bax (BA13I), UAS-Bax 30–
192(DBA8IA) and UAS-Bcl-2 (BC24III) were tested for
viability and wing defect using vg-GAL4 with similar
results (Table 2). Thus, the experiments using the heterol-
ogous model system of Drosophila melanogaster recapitu-
lated the observation of inefficient inhibition of Bax 30–
192 by anti-apoptotic proteins in mammalian cells.Page 2 of 16
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mutants is inhibited by Bcl-xL
To assess the contributions of the TM domains in Bax 30–
192 cytotoxicity, additional regions were deleted (Figure
3A). Apoptosis triggered by a mutant devoid of the C-ter-
minal TM2 domain (Bax 30–171) is Bcl-2 independent,
whereas apoptosis triggered by Bax 1–171 is inhibited
(Figure 3B). However, it should be noted that apoptosis
triggered by this construct was considerably lower than
that triggered by full-length Bax thereby confounding
interpretation of the data. Bax 30–105 which lacks any
putative or experimentally proven TM domain but retains
the BH3 domain triggered high levels of apoptotic dam-
age, which was blocked by Bcl-xL or Bcl-2 (Figure 3C).
We then tested the deletion mutants for regulation by Bcl-
xL in the HEK cell line as the larger size and adherent
nature of the cells facilitates assessment of apoptotic dam-
age and subcellular distribution of GFP-tagged proteins.
Bax induced apoptosis was effectively blocked by Bcl-xL;
apoptosis triggered by Bax 30–192 was poorly inhibited,
and apoptosis triggered by Bax 30–105 was blocked by
ectopically expressed Bcl-xL in this cell line (Figure 3D).
Jurkat cells express lower levels of Bax protein compared
to the HEK cell line arguing against interactions with
endogenous Bax accounting for the responses of the dele-
tion mutants.
Bcl-xL regulation of Bax 30–192 and Bax 30–105 
colocalization with Bid and Bim
The first alpha helix (amino acids 16–35) in the Bax N-ter-
minus is implicated in interactions with activator BH3-
only proteins [15,28,29]. In apoptotic cells, Bax clusters
co-localized with Bid or Bim (Figure 4A and 4B, upper
panel). In cells expressing Bcl-xL, Bid and Bim are evenly
distributed and do not overlap Bax-GFP (Figure 4A and
4B, lower panel). Bax 30–192-GFP tends to coalesce into
a large cluster and overlaps with regions of intense stain-
ing with Bid or Bim (Figure 4C and 4D upper panel).
However, there is no change in the largely punctate distri-
bution of Bax 30–192 or the overlap with Bid or Bim in
cells co-expressing Bcl-xL (Figure 4C and 4D, lower panel).
Since Bax 30–105 triggered Bcl-xL dependent apoptosis
although it did not localize to mitochondria (Figure 5D),
we asked if it triggered the activation of endogenous Bax.
Changes in Bax conformation consistent with its activa-
tion reveal an epitope in the N-terminus that can be
detected using a specific antibody clone 6A7 [35]. Bax 30–
105 lacks the relevant section of the N-terminus, and 6A7
reactivity in cells expressing Bax 30–105 indicated the
activation of endogenous Bax (Figure 4E). This reactivity
was lost in cells that express Bax 30–105 and Bcl-xL (Figure
4F). Further, endogenous Bax as detected by the reactivity
of clone 6A7 colocalized with Bid and Bim and this was
regulated by Bcl-xL (Figure 4E and 4F).
Table 1: Percent viability with tissue specific GAL4 drivers
vg- GAL4 twist- GAL4 scalloped- GAL4 eyeless- GAL4 collagen- GAL4
UAS-Bax-GFP 6.8 7.6 0 0 0
(BA64III) (36/527) (46/602) (0/141) (0/96) (0/130)
UAS-Bax30–192-GFP 8.9 0.6 1.6 0 0
(DBA8II) (55/616) (2/315) (1/59) (0/120) (0/137)
UAS-Bcl-2 90.4 104 97.5
(BC57I) (377/417) (259/248) (39/40)
UAS transgenic lines for Bax-GFP (BA64III) or Bax 30–192-GFP (DBA8II) or Bcl-2 (BC57I) were screened for lethality using various tissue specific 
GAL4 lines as indicated. Percent viability was calculated by assessing the number of Bax-GFP or Bax 30–192-GFP or Bcl-2 expressing flies compared 
to the appropriate sibling control that eclosed at 25°C. Numbers in parenthesis indicate animals screened for analysis.
Inhibition of Bax and Bax 30–192 by Bcl-2 and Bcl-xLFigure 1
Inhibition of Bax and Bax 30–192 by Bcl-2 and Bcl-xL. 
A, GFP (1 μg), Bax-GFP (3 μg) or Bax 30–192-GFP (3 μg) 
with or without Bcl-xL (5 μg) were transfected in Jurkat cells. 
GFP positive cells were assessed for apoptotic nuclear dam-
age. B, Jurkat cells were transfected with GFP (1 μg), Bax-
GFP (3 μg) or Bax 30–192-GFP (3 μg) with or without Bcl-2 
(5 μg) and assessed for apoptotic nuclear damage 12 hours 
post-transfection. The data are presented as mean ± SD 
derived from three-four independent experiments. *p < 
0.001Page 3 of 16
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attenuates inhibition by Bcl-xL but triggers caspase-9 
dependent apoptosis
A construct that included the TM1 domain comprising the
α5–α6 helices, but not the N-terminal 29 amino acids
(Bax 30–146) (Figure 5A) triggered Bcl-xL independent
cytotoxicity (Figure 5B) indicating that the TM1 domain
interfered with the anti-apoptotic function of Bcl-xL. Since
Bax function converges on the activation of caspase-9 [36]
we analyzed apoptotic damage induced by Bax, Bax 30–
146 or Bax 30–105 when co-expressed with a construct
that is a dominant-negative inhibitor of caspase-9
(DNC9) [37,38]. Apoptosis triggered by all the mutants
tested, including Bax 30–192 (data not shown) was
blocked by the co-transfection of DNC9 in HEK cells (Fig-
ure 5C) and in the Jurkat cell line (data not shown). The
data show that all the constructs tested activate a caspase-
9 mediated apoptotic cascade as has been established for
Bax.
Sub-cellular fractionation of HEK cells (Figure 5D) trans-
fected with the relevant constructs showed that Bax is
present in both the cytosolic and mitochondrial fractions,
whereas increased amounts of Bax 30–146 was detected in
the mitochondrial fractions (Figure 5D, upper and middle
panel). In many experiments, the distribution of Bax 30–
146 and Bax 30–192 was skewed to the mitochondrial
fraction (not shown). Expectedly, Bax 30–105 was con-
sistently detected only in the cytosolic fraction. The mito-
chondrial matrix protein Cox-4 was used to ascertain
purity of the fractions.
Bcl-xL associates with but does not regulate the 
localization of N-terminal deletion constructs
Subsequently we assessed the cellular distribution of the
constructs using GFP to report on Bcl-xL regulation of Bax
localization. In the absence of exogenous Bcl-xL, the distri-
bution of Bax, Bax 30–146 and Bax 30–192 is punctate in
apoptotic cells whereas, Bax 30–105 is diffuse (Figure 6A).
In cells co-transfected with Bcl-xL (RFP-Bcl-xL), Bax distri-
bution is rendered diffuse (Figure 6B) as opposed to Bax
30–146 or Bax 30–192, where the punctate distribution is
largely unchanged by Bcl-xL (Figure 6B). The distribution
of Bax 30–105 was not changed by Bcl-xL (Figure 6B). The
distribution of Bax in punctate or diffuse patterns in the
presence or absence of Bcl-xL is plotted in Figure 6C. The
values are derived from an assessment of approximately
200 cells in random fields in each experiment. This exper-
iment shows that in Bax constructs which lack the first 29
amino acids Bcl-xL regulation of cellular distribution is
compromised.
Ectopically expressed Bcl-xL immunoprecipitated cotrans-
fected Bax, Bax 30–146 or Bax 30–105 (Figure 6D) indi-
cating that association with Bcl-xLis not impaired in the
absence of the first twenty nine residues in Bax protein.
The Bax N-terminus regulates inhibition by Bcl-xL
Since Bcl-xL poorly regulated Bax 30–146 or 30–192
despite the association with the protein, we tested if the N-
terminus can modulate this function. Apoptosis triggered
by Bax 1–146 which includes the N-terminus and the TM1
domain was efficiently blocked by RFP-Bcl-xL (Figure 7A).
Bax 1–146 immunoprecipitates Bcl-xL and is detected in
The N-terminal deletion mutant is not regulated by Bcl-2 in Drosophila el nogas erFigure 2
The N-terminal deletion mutant is not regulated by 
Bcl-2 in Drosophila melanogaster. A, Cell lysates of S2 
cells transfected with UAS-GFP (lane 1), UAS-Bax-GFP (lane 
2) or UAS-Bax 30–192-GFP (lane 3) along with actin-GAL4 
for 24 hours were assessed by western blot analysis using an 
anti -GFP antibody. B, Viability of flies was assessed in the 
indicated UAS transgenic lines driven at 25°C by vg-GAL4 
(left panel) or twist-GAL4 (right panel). Viability is repre-
sented as the percentage of eclosed adult flies expressing 
Bax-GFP or Bax 30–192-GFP with respect to the appropriate 
sibling controls. The numbers over each bar indicate the 
total number of flies screened in the group. C-H, Wing phe-
notypes in vg-GAL4 flies sibling controls (C); transgenic fly 
lines of UAS-Bax-GFP (D); UAS-Bax 30–192-GFP (E); Bcl-2 
(F); Bax-GFP + Bcl-2 (G) or Bax 30–192-GFP + Bcl-2 (H). I, 
Wing phenotypes of flies expressing Bax-GFP or Bax 30–
192-GFP were categorized as illustrated. Representative 
images are shown. Arrow indicates notched margin of the 
wing obtained in few animals.Page 4 of 16
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Furthermore, the punctate distribution of Bax 1–146 in
apoptotic cells redistributes to a diffuse pattern in cells
that co-express Bcl-xL (Figure 7C). The distribution of Bax
1–146 overlaps significantly with that of Bcl-xL (Figure
7C). The change in distribution of Bax 1–146 in response
to co-expressed Bcl-xL is shown (Figure 7D). In a construct
that lacks the TM domains, the N-terminus did not mod-
ulate Bax-BH3 function (Figure 7E).
Phosphorylation dependent modifications that change
protein conformation regulate the apoptotic function of
Bcl-2 family proteins. Bax-induced apoptosis is inhibited
by the serine-threonine kinase Akt (Figure 7F and 7H).
This regulation was compromised in a Bax construct (Bax-
Ala3) with alanine substitutions of the Ser/Thr residues
(T14, S15, S16) in the N-terminus which was refractory to
inhibition by Akt (Figure 7F and 7H). The modification in
the N-terminus however, did not interfere with Bcl-xL
inhibition of Bax-Ala3 induced apoptosis (Figure 7G and
7I).
The N-terminus regulates sensitivity to inductive stimuli 
and inhibition by Bcl-xL
The deletion mutants were tested in a cellular system
where Bax activity is regulated by externally applied stim-
uli [11,39]. In Cos-7 cells, staurosporine (STS) triggered
the translocation of ectopically expressed Bax and was a
potent inducer of Bax-mediated cytotoxicity, which was
inhibited in cells co-expressing Bcl-xL (Figure 8A). Bax 30–
192 and Bax 30–146 localized into puncta (data not
shown) or large clusters and triggered high levels of apop-
totic damage which were not further enhanced by STS
(Figure 8B and 8C) or inhibited by Bcl-xL (Figure 8B and
8C). Bax 1–146 is largely diffuse but also localizes as
puncta and is a potent inducer of Bcl-xL dependent cyto-
toxicity in response to STS (Figure 8D). Bax 30–105 trig-
gered apoptosis in the absence of STS although Bcl-xL
inhibited apoptotic damage in the presence or absence of
the apoptotic stimulus (Figure 8E).
The data thus far suggested that apoptosis triggered by Bax
30–146 and Bax 30–192 should not depend on endog-
enous Bax or Bak, whereas Bax 30–105 induced apoptosis
may depend on these proteins. MEF deficient for both Bax
and Bak were therefore tested for susceptibility to apopto-
sis by the Bax deletion mutant constructs. Confirming
these predictions Bax and Bax 30–192 but not Bax 30–105
triggered apoptosis in Bax/Bak deficient cells (Figure 8F).
TM1 helices of full-length Bax are structural antagonists to 
Bcl-xL
In an attempt to elucidate structural correlates if any, of
the phenotypes presented by the mutants we turned to a
sequence-based analysis of the interacting proteins. The
three-dimensional structures of full-length Bax sequence
and deletion mutants have been obtained from homology
modeling, using MODELLER (version 8v1) starting from
the human protein that has 92% sequence identity. The
homology model of Bax was examined using the program
DIAL [40]. The deletion experiments, using mutants lack-
ing the first 29 residues, suggest that major structural alter-
ations in full-length Bax involving the N-terminal 29
residues, influence the penultimate helix connecting TM1
and TM2 regions in the three-dimensional model of full-
length Bax (Figure 9A). In order to test if there is structural
equivalence between the anti-apoptotic protein Bcl-xL and
regions in Bax, we examined full-length Bcl-xL and Bax for
sub-optimal sequence similarity. A high gap penalty of
400 was employed to align the two sets of sequences using
MALIGN [41]. In particular, we notice that the first helix
of TM1 (TM1.1 helix) and the second helix of TM1
Table 2: Percent viability and extent of wing defect with vg-GAL4 for additional UAS transgenic lines
% viability vg-GAL4 % viable flies strong 
wing defect
% viable flies mild wing 
defect
% viable flies no wing 
defect
UAS-Bax-GFP 9.5 41.3 55.1 0.03
(BA13I) (29/303) (12/29) (16/29) (1/29)
UAS-Bax30–192-GFP 12 65.2 30.4 4.3
(DBA8IA) (26/216) (15/26) (7/26) (1/26)
UAS-Bax-GFP; 78.6 0 0 100
UAS-Bcl-2 (BA13I;BC24III) (48/61) (0/48) (0/48) (48/48)
UAS-Bax30–192- GFP; 35.09 84.9 15.09 0
UAS-Bcl-2 (DBA8IA; 
BC24III)
(53/151) (45/53) (8/53) (0/53)
Additional UAS transgenic lines for Bax-GFP (BA13I) or Bax 30–192-GFP (DBA8IA) or Bax-GFP+Bcl-2 (BA13I; BC24III) or Bax 30–192-GFP+Bcl-2 
(DBA8IA; BC24III) driven by vg-GAL4 were assessed for the viability of flies at 25°C as described in Figure 2B. The eclosed adult flies expressing 
Bax-GFP or Bax 30–192-GFP were analyzed for the extent of wing defect and categorized as depicted in Figure 2I. The percentage of flies for the 
wing defect was calculated with respect to the total number of eclosed flies expressing Bax-GFP or Bax 30–192-GFP. Numbers in parenthesis 
indicate flies screened for analysis.Page 5 of 16
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Apoptosis triggered by TM deletion mutants is inhibited by Bcl-xLFigure 3
Apoptosis triggered by TM deletion mutants is inhibited by Bcl-xL. A, Schematic representation of the GFP tagged 
Bax constructs used in functional assays. The numerals indicate the amino acid residue number in the Bax protein (192 amino 
acids). TM1: transmembrane domain 1, TM2: transmembrane domain 2. B-D, Apoptotic nuclear damage in cells assessed 12–15 
hours post-transfection in B, Jurkat cells transfected with GFP, Bax 30–171-GFP or Bax 1–171-GFP with or without Bcl-2 as 
indicated. The data in the figure is normalized to nuclear damage in GFP or GFP + Bcl-2 transfected cells. C, Jurkat cells trans-
fected with GFP, Bax 30–105-GFP (3 μg) with Bcl-2 (3 μg) or Bcl-xL (3 μg). D, HEK cells transfected with Bax-GFP (1 μg), Bax 
30–192-GFP (1 μg) or Bax 30–105-GFP (1 μg) with or without Bcl-xL (1 μg). Inset, shows the levels of Bax, Bcl-2 and Bcl-xL as 
determined by western blot analysis of the Jurkat and HEK cell lines. The data are presented as mean ± SD derived from a min-
imum of three independent experiments. **p < 0.01; *p < 0.001.
BMC Cell Biology 2007, 8:16 http://www.biomedcentral.com/1471-2121/8/16(TM1.2 helix) have significant sequence similarity with α-
5 and α-6 of Bcl-xL and related anti-apoptotic proteins,
respectively (Figure 9B). This is supported by previous
structural studies where Bcl-xL was co-crystallized with
BH3-region of Bim and both helices α-5 and α-6 of Bcl-xL
in this complex interact with the BH3 of Bim [9]. This sug-
gests that the presence of TM1 region could act as struc-
tural antagonists for the interaction of Bcl-xL with Bax.
Furthermore, the BH2 region of Bcl-xL shows local
sequence similarity with the penultimate BH2 helix in Bax
(Figure 9C).
Discussion
The BH3 domain is critical to several interactions within
the Bcl-2 family [5-9] and the anti-apoptotic proteins Bcl-
2 and Bcl-xL regulate Bax via interactions involving this
domain [5,42]. However, mutations in the Bax-BH3
domain which disrupt interactions with pro-survival pro-
teins do not always disrupt regulation by the latter [17,43-
45]. The N-terminus of Bax is implicated in the regulation
of its function by Bcl-2/Bcl-xL and activator BH3-only pro-
teins [[15,22,23] and [46]]. Here we show that the BH3
and TM1 domains are adequate for association with Bcl-
xL and localization to mitochondria respectively, but an
intact N-terminus plays a non-redundant role in the regu-
lation of Bax cytotoxicity by Bcl-xL.
In contrast to Bax [11,15,26], the distributions of Bax 30–
192 or Bax 30–146 were largely unchanged by Bcl-xL (Fig-
ure 6B–C). The TM1 domain/α5–α6 helices (amino acids
Bcl-xL regulation of colocalization with Bid and Bim in HEK cellsFigure 4
Bcl-xL regulation of colocalization with Bid and Bim in HEK cells. A and B, HEK cells transfected with Bax or Bax and 
Bcl-xL were stained for Bid or Bim. C and D, As in A, except that cells were transfected with Bax 30–192 with or without Bcl-
xL. E and F, Cells transfected with Bax 30–105 with and without Bcl-xL were stained with clone 6A7 and Bid or Bim. Nuclear 
morphology was assessed by staining with Hoechst 33342. Single confocal planes of cells imaged at 60× magnification are 
shown. Scale bar: 10 microns.Page 7 of 16
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cytochrome c release from mitochondria in cell-free
assays [29,33]. The substitution of charged residues in the
α5–α6 helices of Bax resulted in its constitutive localiza-
tion to mitochondria, akin to gain-of-function mutants
and increased binding to Bcl-xL [47]. Despite consistent
differences from Bax in regulation by Bcl-xL, the N-termi-
nal deletion mutants immunoprecipitated ectopically
expressed Bcl-xL (Figure 6D). This is not unexpected as the
association of apoptotic with anti-apoptotic proteins does
not culminate in the inhibition of pro-apoptotic activity
[17,43-45,48]. Further, Bax 30–192 triggered caspase-9
dependent apoptosis and localized with Bid and Bim con-
ventionally associated with regulated activity of Bax
[15,48,49] a distribution largely unchanged by Bcl-xL. In
our experiments the effect of the TM1 domain was miti-
gated by the inclusion of the N-terminal region i.e. Bax-1–
146 (Figure 7).
The anti-apoptotic proteins Bcl-2 and Bcl-xL are not func-
tionally equivalent and the differences in the regulation of
Bax 30–105 (Figure 3C) likely reflect differences in affini-
ties of the mutant for the anti-apoptotic proteins. Such
differences in functional interactions between pro-sur-
vival members and the pro-apoptotic or BH3 only pro-
teins (BOPs) have been previously reported [17,50]. The
The TM1 domain regulates inhibition by Bcl-xLFigure 5
The TM1 domain regulates inhibition by Bcl-xL. A, Schematic representation of Bax and Bax 30–146. B, HEK cells trans-
fected with Bax 30–146-GFP (1 μg) with or without Bcl-xL (1 μg) and assessed for apoptotic nuclear damage after 15 hours of 
culture. Data are normalized for apoptotic damage triggered by GFP alone in both conditions. C, HEK cells were transfected 
with 1 μg GFP or Bax-GFP or Bax 30–146-GFP or Bax 30–105-GFP with or without 2 μg dominant negative caspase 9 
(DNC9). Apoptotic nuclear damage was assessed after 15 hours of culture. Data is normalized to damage in cells transfected 
with GFP alone or GFP + DNC9 transfected cells. D, HEK cells transfected with Bax-GFP or Bax 30–146-GFP or Bax 30–105-
GFP were harvested after 15 hours of culture and subjected to sub-cellular fractionation. The cytosolic (Cyto) and membrane/
mitochondrial (Mito) fractions were assessed for GFP and Cox4 distribution by western blot analysis. WCL: whole cell lysate. 
Values in the anti-GFP blots are derived from densitometry analysis and indicate the amount of GFP detected in the specific 
fraction relative to the total signal in the mitochondria and cytosol fractions. The data are presented as mean ± SD derived 
from a minimum of three independent experiments. **p < 0.01; *p < 0.001.Page 8 of 16
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The Bax N-terminus or TM1 domain is not essential for association with Bcl-xLFigure 6
The Bax N-terminus or TM1 domain is not essential for association with Bcl-xL. A, HEK cells transfected with Bax-
GFP, Bax 30–192GFP, Bax 30–146 GFP, Bax 30–105 GFP or RFP-Bcl-xL were harvested after 15 hours and imaged using confo-
cal microscopy. Representative images (processed as described in methods) are shown. Scale bar: 10 microns B, HEK cells 
transfected with each of the constructs in A and RFP-Bcl-xL were harvested 15 hours post-transfection. Confocal images for 
distribution of Bax constructs (green) and RFP-Bcl-xL (red) were assessed for co-localization (Merge, right panel). Scale Bar: 10 
microns. Representative images (each corresponding to a single image field) are shown. C, From the experiment in B, cells pos-
itive for GFP and RFP were scored for punctate or diffuse patterns of GFP by microscopy. The data are representative of two 
independent analyses. D, HEK cells transfected with Bax-GFP + Bcl-xL (left panel) or Bax 30–146-GFP + Bcl-xL (middle panel) 
or Bax 30–105-GFP + Bcl-xL (right panel) were harvested after 15 hours of culture. Bcl-xL was immunoprecipitated from cell 
lysates and the immunoprecipitates assessed by western blot analysis for Bax or the mutant constructs using an antibody to 
GFP and for the presence of actin. WCL represents the CHAPS buffer solubilized whole cell lysate, which was used for immu-
noprecipitation.
BMC Cell Biology 2007, 8:16 http://www.biomedcentral.com/1471-2121/8/16BOPs are thought to be critical mediators of the activation
of Bax/Bak although the mechanism underlying this acti-
vation is unresolved. Thus, 'activator" BOPs (Bid, Bim and
Puma) have been reported to directly bind Bax and Bak
triggering activation of the latter and are assisted in this
function by "derepressor" BOP (Noxa, Bad etc.) which
bind anti-apoptotic proteins [17]. On the other hand
there is compelling evidence that BOP trigger the activa-
tion of Bax principally by binding Bcl-2/Mcl-1/Bcl-xL [48]
obviating a requirement for direct interactions with Bax/
The Bax N-terminus regulates susceptibility to inhibition by anti-apoptotic moleculesFigure 7
The Bax N-terminus regulates susceptibility to inhibition by anti-apoptotic molecules. A, Apoptotic nuclear dam-
age (15 hours post-transfection) was assessed in HEK cells transfected with Bax 1–146-GFP with or without RFP-Bcl-xL. B, 
HEK cells transfected with Bax 1–146 GFP and Bcl-xL were harvested after 15 hours of culture and Bcl-xL immunoprecipitated 
from the cell lysate. The precipitated complex was analyzed for Bax 1–146-GFP and actin by western blot analysis. WCL is the 
CHAPS buffer-solubilized whole cell lysate used in the immunoprecipitation. HEK cells transfected with Bax 1–146-GFP were 
harvested 15 hours post-transfection and processed to enrich for the cytosol (Cyto) and the membrane/mitochondrial (Mito) 
fractions. The distribution of GFP and Cox4 was determined by western blot analysis. WCL represents the whole cell lysate. 
Numbers below the blots are the densitometric analysis of the GFP signal in the specific fraction relative to the total in the 
mitochondria and cytosol fractions. C, HEK cells expressing Bax 1–146 alone or Bax 1–146+RFP-BclxL were assessed for distri-
bution as described in 6B. E, Apoptotic nuclear damage was assessed in HEK cells 18–20 hours following transfection with 
combinations of constructs shown in the panels. F and G, Regulation of Bax and Bax-Ala3 induced apoptosis by constitutively 
active (CA)- Akt (F) and Bcl-xL (G). The data in all panels are presented as mean ± SD and are derived from three-five inde-
pendent experiments. H and I, HEK cells transfected with Bax-GFP or Bax-Ala-3 with CA-Akt and Mito-dsRed2 or RFP-Bcl-xL 
where indicated were harvested 15 hours post-transfection. Confocal images for distribution of GFP tagged constructs of Bax 
(green) and Mito-dsRed2 (red) or RFP-Bcl-xL (red) were assessed for co-localization (Merge). Scale Bar: 10 microns. Repre-
sentative images (each corresponding to a single image field) are shown. *p < 0.001Page 10 of 16
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BMC Cell Biology 2007, 8:16 http://www.biomedcentral.com/1471-2121/8/16Bak except in some conditions [51]. Bax 30–105 fulfills
several criteria associated with BH3 domain only proteins
triggering activation of endogenous Bax (which colocal-
ized with Bid and Bim); Bcl-xL dependence and in the
requirement for endogenous Bax-Bak for apoptotic func-
tion (Figure 3C–D, 4E–F and 8F).
We do not know the mechanism underlying the lack of
regulation of Bax 30–192 and Bax 30–146 by Bcl-xL. The
constitutive association of Bax 30–192 and 30–146 with
Bcl-xL may arise from structural changes in the deletion
mutants culminating in a greater affinity (compared to
Bax) for the anti-apoptotic protein. This may permit the
mutants to sequester ectopically expressed Bcl-xL. On the
other hand the association may impose conformational
changes on Bcl-xL such that the latter is rendered function-
ally inactive and thereby unable to regulate apoptotic
damage. That the pattern of Bid distribution in cells
expressing Bax or Bax 30–105 changes on co-expressing
Bcl-xL but not in cells that express Bax 30–192 provides
some support for this possibility.
Analysis of local sequence similarities indicate that sub-
optimal alignments reside at the interacting site of Bcl-xL
and Bax TM1 helices. Sub-optimal sequence alignment
between TM1 of Bax and α5–α6 of Bcl-xL suggests that the
TM1 might block a productive functional interaction with
Bcl-xL. The absence of N-terminal residues in Bax leads to
Responses of Bax deletion mutants to an inductive stimulusFigure 8
Responses of Bax deletion mutants to an inductive stimulus. A-E, Cos-7 cells were transfected with indicated con-
structs as described in methods and apoptotic nuclear damage assessed 3–4 hours after the addition of STS (gray bars). The 
bars in black indicate apoptotic damage in the absence of STS. F, MEF that are deficient for both Bax and Bak were assessed for 
susceptibility to Bax, Bax 30–105 and Bax 30–192. Bax 30–105 was tested in the presence (gray bars) or absence (black bars) 
of STS. *p < 0.001Page 11 of 16
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function. The deletion analysis of Bax suggests that the N-
terminal residues that are spatially interacting with the
BH2 helix are absolutely required for (and may drive) the
normal and necessary structural alterations in TM1 helices
such that the anti-apoptotic elements can regulate its
function. These are currently being investigated by
detailed molecular dynamics simulations as well as stud-
ying the effect of additional mutations in Bax. The TM2
region in Bax may not be a crucial structural antagonist to
Bcl-xL since the removal of TM2 results in a mutant (Bax
30–171) whose apoptotic activity is not regulated by Bcl-
xL in the Jurkat and the HEK cell lines. Thus we propose
(as depicted in the model in Figure 10) that the N-termi-
nal "switch" of 29 residues is necessary to produce the
required structural alterations in Bax such that TM1.1 is
displaced from the Bcl-xL interacting site. In the absence of
the N-terminal switch, this natural "trigger" mechanism is
abolished and the TM helices continue to act as 'structural
valves' where the protein remains closed to inhibition by
Bcl-xL-like proteins.
Conclusion
Our experiments extend previous observations that the
Bax N-terminus is an essential component in the regula-
tion of Bax function by anti-apoptotic proteins such as
Bcl-xL. Furthermore we propose that an intramolecular
interaction between the N-terminus and the TM1 may be
the mechanism underlying this regulation.
Structural and sequence analyses of Bax and Bcl-xLproteinsFigure 9
Structural and sequence analyses of Bax and Bcl-xLproteins. A, Schematic representation of the spatial interactions 
between different segments of full-length Bax. The homology model of Bax was examined using the program DIAL [40], origi-
nally meant for recognizing compact structural domains in proteins. Structural segments with similar shading form spatial clus-
ters and subdomains. The BH2 region (residues 145–170) forms a cluster with the N-terminal 29-residues indicating spatial 
proximity between the two segments. B, Sub-optimal sequence alignment between the helices in TM1 region of representative 
pro-apoptotic family members and alpha-5 of anti-apoptotic proteins. Protein names and residue numbers are marked for the 
sake of clarity. C, As for B, but showing the alignment between the BH2 helix of pro-apoptotic proteins and Bcl-xL.Page 12 of 16
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Cells and reagents
Jurkat, HEK and COS-7 cell lines and the Bax-Bak defi-
cient MEF were maintained in culture in medium supple-
mented with antibiotics, glutamine (Invitrogen-Gibco,
Carlsbad, CA) and 5 or 10% fetal calf serum (Hyclone,
Logan, UT). Antibodies were procured from the following
sources: to GFP and Bim from BD Biosciences (Franklin
Lakes, NJ); to Bax and Bcl-2 from Santa Cruz (Santa Cruz,
CA); to Cox-4 and and Alexa Fluor 555/Cy5 conjugated
secondary antibodies from Invitrogen-Molecular Probes;
to Bid from Cell Signaling Technology; to Bcl-xL from
Abcam (Cambridge, UK); actin and clone 6A7 from Neo-
marker (Fremont, CA) respectively. Protein G agarose
beads were from Pierce Biotechnology (Rockford, IL).
Mouse or Rabbit True-Blot HRP (Ebiosciences, San Diego,
CA) was used in the western blot analysis of immunopre-
cipitated proteins. All other chemicals were obtained from
Calbiochem (San Diego, CA) or Invitrogen.
Plasmids
A mammalian expression vector encoding murine full-
length Bax was the kind gift of Peter Vandenabeele (Uni-
versity of Gent, Belgium). Bax-GFP and the deletion
mutants were generated by PCR amplification and sub-
cloning into the pEGFP-N1 vector (BD Clontech, Moun-
tain View, CA) with GFP in-frame at the C- terminus. The
following primers were used to generate the Bax and Bax
mutants: Bax/Bax 1–171/Bax 1–146 forward 5' CCG CTC
GAG ATG GAC GGG TCC GGG 3' Bax 30–192/Bax 30–
171/Bax 30–146/Bax 30–105 forward 5' CCG CTC GAG
ATG TTC ATC CAG GAT 3' Bax/Bax 30–192 reverse 5'
CCC AAG CTT GCC CAT CTT CTT CCA 3' Bax 30–171/
Bax 1–171 reverse 5' CCC AAG CTT CTG CCA TGT GGG
3' Bax 30–146/Bax 1–146 reverse 5'CCC AAG CTT CTC
ACG GAG GAA 3' Bax 30–105 reverse 5' CCC AAG CTT
GAA GTT GCC ATC 3'. The murine Bcl-2 plasmid was
obtained from Upstate (Charlottesville, VA). The domi-
nant negative caspase 9 construct was the kind gift of C.
Vincenz (University of Michigan Medical School, Ann
Arbor, MI) and the human Bcl-xL plasmid was from Rich-
ard J. Youle (National Institutes of Health, Bethesda,
MD). CA-Akt was from Upstate (Charlottesville, VA).
Monomeric RFP (mRFP) plasmid was originally from
Roger Y. Tsien (University of California, San Diego, CA)
and obtained through Satyajit Mayor (National Centre for
Biological Sciences, Bangalore, India). Bcl-xL was sub-
cloned into the pUSEAmp mammalian expression vector
and was also subcloned at the 3' end of mRFP under the
CMV promoter. Mito-DsRed was obtained from V. Sriram
(National Centre for Biological Sciences, Bangalore,
India). The sequence of all constructs was verified by auto-
mated sequencing (Microsynth, Balgach, Switzerland).
The alanine substitution mutant Bax-Ala3 (substituted on
T14, S15 and S16) was generated at Everogen (Moscow,
Russia).
Transient transfections and assay for nuclear damage
Jurkat and 2B4 cells were transfected by electroporation.
Briefly 3–5 million cells were electroporated at 250 V and
960 μF and cultured for 12 hours prior to analysis. HEK
and COS-7 cells were plated at 0.4–0.5 million cells/ml
and MEF at 0.3 million/ml 12–15 hours prior to transfec-
tion. Cells were transfected using lipofectaime 2000 (Inv-
itrogen, Carlsbad, CA) according to the manufacturer's
instructions. Cos-7 cells were transfected with 0.2 μg of
Bax constructs and 2 μg Bcl-xL. 12–15 hours later stau-
rosporine was added at a final concentration of 1 μM and
the cultures continued for an additional 3–4 hours before
analysis.
Transfected cells were harvested and stained for 3 minutes
at ambient temperatures in the dark using the Hoechst
33342 (1 μg/ml) and assessed for apoptotic nuclear dam-
age. GFP positive cells were viewed under the UV filter of
the fluorescence microscope and nuclear morphology
scored for a minimum of 200 cells in each experimental
condition. In a minimum of two experiments in each set
of data samples were scored double-blind. Statistical sig-
nificance of the differences between groups was assessed
by the Student's t-test and is indicated by an * in the fig-
ures.
Sub-cellular fractionation
The protocol followed has been previously described [52].
Briefly, 1 million cells were incubated in 100 μl homoge-
nization buffer (250 mM sucrose, 20 mM Hepes, 10 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, pH 7.2
supplemented with 2 μg/ml aprotinin, leupeptin and pep-
statin) for 15 min on ice. Cells were mechanically dis-
A model summarizing the behavior of deletion mutants of BaxFigure 10
A model summarizing the behavior of deletion 
mutants of Bax. The deletion constructs are named 
according to the beginning and end residue numbers. Differ-
ent regions of Bax: N-terminal 29 residues, BH3 helix, the 
first and second helices of TM1 region (TM1.1 and TM1.2), 
BH2 helix and TM2 region, are color-coded as cyan, red, 
green, blue and purple, respectively. Constructs whose apop-
totic activity is regulated by Bcl-xL are in shaded boxes. The 
open boxes show deletion mutants not regulated by Bcl-xL.Page 13 of 16
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followed by a 30-gauge needle 15 times. Cell lysates were
centrifuged at 750 g for 10 min at 4°C to remove unlysed
cells and nuclei. The supernatant was centrifuged at
12,000 g for 20 min at 4°C to obtain the pellet enriched
in mitochondria and the supernatant enriched for
cytosolic proteins. Equivalent volumes of cytosolic and
mitochondrial fractions were used for western blot analy-
sis to assess the relative distribution of Bax and the
mutants. The densitometry analysis of western blots was
performed using Image Gauge software Version-3 (Fuji-
film Science, Japan)
Immunoprecipitation
In each group two million cells were harvested and lysed
in 500 μl of CHAPS lysis buffer (1% CHAPS in 50 mM
Tris-Cl, 150 mM NaCl, 1 mM EDTA, pH7.4 supplemented
with 2 μg/ml aprotinin, leupeptin, pepstatin, 1 mM PMSF,
1 mM NaF and 1 mM Na3OV4) by 3 freeze thaw cycles in
liquid nitrogen and 37°C followed by an incubation (30
minutes) at 4°C on a cell rotator. The lysate was centri-
fuged at 3000 rpm to remove debris and unlysed cells. The
supernatant was incubated with 10 μg of antibody to Bcl-
xLat 4°C for 1 hour on a cell mixer. 80 μl of washed Pro-
tein-G agarose beads were then added to the sample and
mixed by gentle rotation for another 2 hours at 4°C.
Beads were pelleted by centrifugation at 1700 rpm and
subsequently washed 4 times with chilled PBS. After the
final wash the beads-complex was pelleted by centrifuga-
tion at 2500 rpm and boiled in SDS lysis buffer for 10
minutes before western blot analysis.
Immunochemistry and confocal imaging
Cells washed with PBS and fixed in 4% paraformaldehyde
for 15 minutes at ambient temperature were permeabi-
lized with 0.2% CHAPS in PBS (permeabilization buffer)
for 30 minutes on ice and blocked for 1 hour on ice with
5% BSA diluted in permeabilization buffer. Cells were
incubated with primary antibodies diluted in blocking
buffer for 1–2 hours on ice followed by a wash with per-
meabilization buffer. The cells were finally incubated with
Alexa Fluor 555 and/or Cy5 conjugated secondary anti-
bodies diluted in blocking buffer for 1 hour on ice. Cells
were also counterstained with Hoechst 33342 before the
final wash and imaged.
Cells were imaged using a Bio-Rad MRC 1024 laser scan-
ning confocal microscope equipped with Argon-Krypton
laser and 60X, NA 1.4 objective lens. Fluorescence images
of cells were recorded with sequential excitation and emis-
sion conditions using appropriate optics. The acquired
images were processed for co-localization analysis using
Image J1.34s software. For the analysis of endogenous
Bid, Bim or Bax, samples were imaged using a LSM 510
Meta laser scanning confocal microscope (Carl Zeiss, Jena,
Germany) equipped with Argon, Helium-Neon lasers and
63X, NA 1.4 objective. The fluorescence images for GFP
tagged, Alexa Fluor 555 and Cy5 labeled proteins were
acquired with sequential excitation (488 nm, 543 nm and
633 nm respectively) and emission conditions using
appropriate optics. The nuclear morphology images were
acquired using two photon excitation of single plane with
750 nm pulsed laser (Spectra-Physics, CA). Images were
processed for co-localization analysis using Image J1.34s
and LSM Meta (Carl Zeiss, Jena, Germany) software.
Transgenic flies and genetic interaction studies
Bax-GFP, Bax 30–192-GFP and Bcl-2 were cloned in the
UAS vector pUAST. The resulting plasmids were injected
into yw; +; Ki P(Δ2-3ry+) embryos using standard proce-
dures. Several independent transformant lines were
obtained by P-element transformation for each transgene.
A minimum of two lines in each case were characterized
for further analysis. Bax-GFP insertion was mapped to
chromosomes III and I for BA64III and BA13I transgenic
lines respectively. Bax 30–192-GFP insertion was mapped
to chromosome II and I for DBA8II and DBA8IA fly lines
respectively. Bcl-2 insertion was mapped to chromosome
I and III for BC57I and BC24III fly lines respectively. A sin-
gle copy transformant fly line for each transgene was
crossed to flies carrying vestigial (vg)-GAL4, twist-GAL4,
eyeless-GAL4, scalloped-GAL4 or collagen-GAL4. Flies were
raised on standard Drosophila medium at 25°C.
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